Senior Director, Field Medical Lead-East at Vor Bio

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

The Senior Director, Field Medical Lead (East) must reside in the US Eastern time zone and be an experienced MSL ready for leadership responsibilities. The role requires the ability to engage directly with external experts and support regional field execution, ensuring consistency, quality, and alignment with global and U.S. medical strategy. Candidates should be prepared for progression into formal people leadership and/or medical strategy roles.

Responsibilities

The Senior Director, Field Medical Lead (East) will serve as the scientific face of Vor to healthcare professionals, KOLs, investigators, and advocacy groups in the East territory, delivering unbiased scientific exchange and communicating emerging data. This role involves supporting clinical trial execution, capturing and relaying field medical insights, and representing the company at scientific congresses. Additionally, the incumbent will be a core member of the Medical Affairs Leadership Team, responsible for creating and driving medical strategy, leading and mentoring MSLs, supporting hiring and onboarding, developing field execution frameworks, and partnering on territory planning and tactical execution. Regional initiatives such as congress planning and advisory board logistics will also be led by this individual.

Skills

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters

2015Year Founded

$147.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.

Key clinical trial data updates are not expected until 2025, causing uncertainty.

Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.

The company specializes in innovative treatments for blood cancers like AML.

Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.

FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.

Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI

Try Jobo Free